• Nitrocefin: Practical β-Lactamase Assay Workflows

  2026-09-14

  Nitrocefin converts β-lactamase activity into a rapid yellow-to-red signal for resistance profiling, enzyme characterization, and inhibitor screening. This guide connects practical assay setup with a peptide-discovery workflow reported for TEM-1 β-lactamase, including controls, optimization strategies, and troubleshooting.

• Anti-ROR1 Antibody (Zilovertamab) Guide

  2026-09-13

  Anti-ROR1 Antibody (Zilovertamab) is a humanized IgG1 reagent designed to bind ROR1 and inhibit Wnt5a-induced ROR1 signaling. The F1460 product supports ELISA, FACS, kinetic, functional, and animal-model workflows, but its product-level binding data do not establish clinical efficacy or activity in deoxynivalenol-induced liver injury.

• Concanavalin A Targets Conserved Coronavirus Glycans

  2026-09-12

  This study identifies phylogenetically conserved N-linked glycans near the coronavirus spike S2′ cleavage site as a broad-spectrum antiviral vulnerability. Using fusion, pseudovirus, authentic infection, biochemical, and animal models, the authors show that concanavalin A blocks spike activation and reduces hCoV-NL63 disease-related outcomes in mice.

• Targeting Fructose Metabolism in Cancer Therapy

  2026-09-12

  This 2025 Cancer Letters review integrates fructose transport, the polyol pathway, tumor bioenergetics, mTORC1 signaling, and immune regulation into a unified framework for cancer therapy. Its main practical implication is that fructose metabolism may offer both biomarker opportunities and combination-treatment targets, although the evidence remains primarily mechanistic and preclinical.

• Torin2: Potent mTOR Inhibitor for Cancer Research

  2026-09-11

  Torin2 is a highly potent, selective mTOR inhibitor with a reported EC50 of 0.25 nM in the product potency assay. Its cellular, tissue-exposure, and medullary thyroid carcinoma data support pathway-dissection studies, while recent RNA Pol II research provides a mechanistic apoptosis framework that should not be directly attributed to Torin2 without validation.

• Recombinant Mouse IFN-γ in MASH-HCC Assays

  2026-09-11

  Use Recombinant Mouse IFN-γ as a controlled challenge to distinguish defective tumor antigen presentation from downstream immune-cell failure in MASH-HCC models. This workflow combines cytokine rescue, bile-acid stress, NLRC5/MHC-I readouts, and functional validation for more interpretable immunotherapy studies.

• Difloxacin HCl: Assay Workflows and Use Cases

  2026-09-10

  Difloxacin HCl supports two distinct research paths: bacterial DNA replication inhibition for antimicrobial susceptibility testing and exploratory multidrug resistance reversal through MRP substrate sensitization. This practical guide covers formulation, controls, workflow design, checkpoint-biology context, and troubleshooting without treating research results as clinical recommendations.

• Thymoquinone in Doxorubicin Cardiotoxicity Models

  2026-09-10

  Thymoquinone offers a practical probe for connecting cardiac function, oxidative stress, mitochondrial injury, and ferroptosis in doxorubicin models. This workflow translates recent mouse findings into formulation controls, orthogonal assays, and troubleshooting steps for more reproducible cardioprotection studies.

• From Bile-Acid Subtypes to qPCR Biomarkers

  2026-09-09

  A translational analysis of how bile acid metabolism signatures in colorectal cancer can be converted into reproducible qPCR biomarkers using robust reverse transcription, genomic DNA contamination control, and disciplined validation.

• Peptidisc-Assisted Nanobody Clustering: Study Insights

  2026-09-09

  This bioRxiv preprint describes a peptidisc-assisted strategy for clustering nanobodies through hydrophobic transmembrane segments, producing multimeric assemblies called polybodies. The reported avidity gains, bispecific assemblies, and autofluorescent constructs suggest a flexible route to multifunctional binders, while the preprint status and limited quantitative detail require careful validation.

• SB 225002 and the CXCR2–IL-8 Decision Point

  2026-09-08

  The IL-8 axis is not a single pathway: receptor usage can separate tumor-cell proliferation from neutrophil trafficking. This thought-leadership analysis positions SB 225002 as a selective CXCR2 tool for testing that distinction in inflammation, cancer, and infection-associated microenvironment models.

• Phosphatase Inhibitor Cocktail 1 Workflow

  2026-09-07

  Protect labile phosphorylation states from cell harvest through Western blotting, co-immunoprecipitation, and phosphoproteomic analysis. This workflow combines a practical 1X starting condition with tissue-panel guidance inspired by UPF3A expression research, while highlighting controls and troubleshooting limits.

• Pifithrin-α: Practical p53 Inhibition Workflows

  2026-09-07

  Pifithrin-α provides a reversible way to test whether DNA damage, deltamethrin stress, ferroptosis, or irradiation phenotypes depend on p53 signaling. This guide translates a recent maternal neurotoxicity study into practical cell-based workflows, formulation advice, controls, and troubleshooting strategies.

• EdU Imaging Kits: Reading S-Phase in RCC

  2026-09-05

  EdU Imaging Kits (HF488) provide a precise way to interpret DNA synthesis in renal cell carcinoma models. This article connects EdU click chemistry with the esculin RCC study and offers a practical framework for microscopy, flow cytometry, and orthogonal validation.

• PPT and ERα: From Selective Signal to Translation

  2026-09-05

  PPT (Propyl Pyrazole Triol) provides a precise way to perturb ERα while minimizing ERβ-driven ambiguity. This thought-leadership article connects its receptor-level pharmacology with the FOXM1–ERα network reported in female lung adenocarcinoma and offers a practical framework for translational validation.

8512 records 4/568 page Previous Next 12345 下5页 Last page